New drug cocktail aims to tame stubborn arthritis
NCT ID NCT07491016
First seen Mar 30, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This study is testing whether a combination of two drugs, telitacicept and baricitinib, can help people with difficult-to-treat rheumatoid arthritis. The trial will enroll 30 adults aged 18 to 85 who have not responded to other treatments. Researchers will measure joint swelling and pain, and watch for side effects like liver or kidney problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Provincial People's Hospital
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
telitacicept and baricitinib
What this could lead to
If it works, this could offer a new treatment option for people with rheumatoid arthritis that hasn't improved with standard therapies.
What could go wrong
This is a very small, early-stage study with only 30 participants, so results may not apply to everyone. The combination may cause side effects like liver or kidney issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.